Key Facts
In addition to drug screening of approved drugs for personalised cancer therapeutics, we have recently secured licensing of investigational drug screening for pharma purposes and drug discovery, representing a major asset for future development and a lucrative revenue stream. We aim to identify at least 1 novel compound for colorectal cancer targets by the end of 2021. SOme of our Awards / collaborations: Selected as ‘Top 10 to watch in Precision Medicine’ by Clinical Omics. We have established relationships with partners and oncologists worldwide at over 15 medical centers/oncologists each treating hundreds of patients annually and are in the process of developing further collaboration agreements with key medical platforms to benefit from commercial synergies. As our in vivo, high throughput drug screening platform is also attractive and scalable for biopharma discovery and development, we have started to also focus business development efforts in this area and have already established collaborations for screening of molecules on our patient avatar models. Some of our most recent key partners / collaborators include: London In Vitro Diagnostics Center NHS Trust, Guys and St Thomas (UK), Sarah Cannon (US and UK), King Abdullah International Medical Center (Saudi Arabia), Beverly Hills Cancer Center (US), Center for Nutraceutical and Pharmaceutical Materials Myongji University (South Korea), Medicision (Australia/Asia), Medivizor (Israel), Lausanne Medical Center (Switzerland), Qatar National Cancer Control Center (Qatar), Acindes (South / Central America), Gemseki (Japan) Selected as ‘1 in 20 top Digital Health companies in Europe’ by TechTour Awarded Eureka AI/QT Grant- £792k for lung AI product Awarded Innovate UK Grant- £477k for GI cancer study at Imperial London IVD NHS Trust P4 Precision Medicine Accelerator 2020 (Barclays-UCL) Health Hub Vienna Participant 2020 Invest Horizon 2020 Accelerator cLAB Ventures Accelerator 2020 Selected as one of Top 3 Grind Start-ups, one of ‘7 exciting start-ups to look out for’ and one of ‘7 women-founded start-ups you need to know about’ by Start-up Grind, Silicon Valley 2019/2020
Successes in UK/NHS
We have partenred up with Imperial College / NHS Trust for the project: Application of Whole Genome Sequencing Approaches to Cancer – Personalised therapies based on simultaneous targeting of complex oncogenic networks identified by WGS – Innovate UK grant awarded: £363,624. One of the Innovate UK grants we have been awarded will allow us to provide personalised treatment recommendations to a subset of hard-to-treat gastro-intestinal cancer (GIC) patients, in collaboration with NIHR - London In Vitro Diagnostics Co-operative. This funding and support from Innovate UK is enabling us to create personalised treatment plans for patients in an NHS setting, collecting valuable outcomes and health economic data vital to more widespread adoption. We hope this facilitates the adoption of our technology (the Personal Development Process) into widespread clinical practice to improve the quality of cancer patient care across public health care.Company details
Solutions
Augmenting healthcare professionals
Specialism
Decision Support and treatment planning
Company details

Want to connect with this innovator?
Make an enquiryWebsite
vivantx.com/Markets already exporting to
US, UK, Saudi, Argentina/South America/Switzerland/Australia. We cater to pateints/oncologists/biopharma worldwide from our lab in London. Customers do not have to physically visit us for our services.
Desired Markets
Middle East countries, Germany, France, China, Japan (we are open to others)
Desired customer types
Cancer patients (with primary focus on Gastrointestinal cancer), Oncologists (focused on GI), Biopharma (drug discovery), insurers, public healthcare, private healthcare, Global Healthcare centres